Medical Resource Association today officially announced their Third Annual Science in the City International - Paris 2026, a premier international symposium dedicated to the advancement of cannabinoid therapeutics, physician education, and clinical integration. The event will convene global leaders in medicine, research, pharmacy, regulation, and industry at a pivotal moment for France as medical cannabis enters a new phase of clinical and policy development. This event signifies a pivotal moment in the evolution of medical cannabis in France and Europe.

Building upon the success of previous two editions in Bordeaux; the expansion to Paris reflects France's emergence as one of Europe's most consequential environments for cannabinoid therapeutics and emerging pharmaceutical innovation. As the nation advances toward a permanent medical cannabis framework, Paris has become a natural convening point for regulators, clinicians, researchers, and industry leaders committed to accelerating evidence-based medicine, physician education, and responsible patient access. 

The symposium will present expert faculty yet again bringing together physicians, researchers, prescribers, pharmacist, healthcare executives, regulators, industry innovators, and patient advocates to examine the future of pharmaceutical innovation and emerging therapeutics while advancing evidence-based cannabinoid medicine across Europe.

Healthcare and life sciences are entering a defining period of transformation. Advances in pharmaceutical medicine, precision health, and the emerging science of plant-based medicine are reshaping how care is delivered, while unprecedented opportunities for collaboration emerge across academia, industry, government, and clinical practice. Science in the City International - Paris 2026 convenes leaders who recognize that the future of healthcare will be built through partnership, scientific exchange, and cross-border innovation.

"The remarkable response to our Bordeaux editions showed that the global healthcare community is seeking a forum where science meets execution and collaboration drives innovation," said Charles S. Messal, COO of Medical Resource Association. "Paris provides the perfect backdrop to convene international leaders committed to advancing medicine and improving patient outcomes worldwide."

“The timing is significant”, says Timothy L. Beury, CFO of Medical Resource Association. As France advances toward a permanent medical cannabis framework, there has never been a more important moment for scientific collaboration, physician education, and evidence-based discussion. Paris, a leading global center of science, medicine, and innovation, offers the ideal setting to explore the science, policy, education, and clinical integration needed to advance cannabinoid medicine across Europe, while examining the future of pharmaceutical innovation and emerging therapeutics.

The symposium will extend beyond Paris through their "Live from New York" global simulcast connecting international audiences and strengthening cross-border scientific exchange and collaboration. 

"The next chapter of cannabinoid medicine in France is being written now," said Kristen M. Beury, Founder and CEO of Medical Resource Association. "Science in the City International - Paris 2026 is more than a symposium; it is a convening of the individuals and institutions committed to advancing evidence-based medicine, physician education, and responsible patient access. We are honored to bring the global community together in Paris during this historic moment." 

Registration for is now open. Physicians, researchers, pharmacists, healthcare executives, regulators, industry innovators, and patient advocates are invited to participate.

Organizer Contact:
Charles Stéphane Messal
E-Mail: info@mrasrq.com
Tel: 941-726-3169 USA 
Tel: +33 5 37 10 00 69 France

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.